Weekly Digests
‹ Back to July

Reduce, Reuse, Recycle to improve anti-CTLA-4 therapy

July 24, 2019

Targeting the checkpoint molecule CTLA-4 using antibodies has been relatively successful as a cancer immunotherapy, however, clinical benefits often come with severe and sometimes dose-limiting immune-related adverse events (irAEs). In a paper recently published in Cell Research, Zhang, Du, and Liu et al. investigated why different CTLA-4 targeting antibodies induce different degrees of both efficacy and irAEs, and developed a strategy that may improve both the safety and efficacy of anti-CTLA-4 antibodies.

While the exact mechanism of CTLA-4-targeted antibodies like ipilimumab and an IgG1 variant of tremelimumab (TremeIgG1) is still ambiguous, they likely work in part by blocking CTLA-4 from interacting with CD80/CD86, thereby allowing CD28 co-stimulation by these ligands in TCR-activated T cells. The same antibodies may also work in part by binding to CTLA-4 en masse on Tregs, flagging them for depletion via antibody-dependent cellular cytotoxicity (ADCC). While these particular antibodies can be effective in inducing immune responses to cancer, they are also prone to inducing serious irAEs. By contrast, some other anti-CTLA-4 antibodies, like HL12 and HL32 (previously identified by the authors), are less prone to inducing irAEs. Investigating this distinction, Zhang, Du, and Liu et al. noticed an interesting correlation: irAE-prone anti-CTLA-4 antibodies led to significant downregulation of CTLA-4 on target cells, while non-irAE-prone antibodies did not.

Further investigating the difference in CTLA-4 downregulation between different antibodies, the researchers found that all four anti-CTLA-4 antibodies localized with CTLA-4, leading to rapid internalization of the complex, but that only ipilimumab and TremeIgG1 subsequently drove CTLA-4 to the lysosomes. Based on prior evidence that pH drops significantly as endocytosed antibody-target complexes transition into lysosomes, the researchers suspected that pH sensitivity of the different antibodies might affect the fate of CTLA-4. They found that the capacity of ipilimumab and TremeIgG1 to bind to CTLA-4 was largely unaffected by pH within a range of 4-7. Meanwhile, HL12 and HL32 were highly sensitive to pH and progressively lost their binding capacity and dissociated from CTLA-4 once the pH dropped below 6.5 – the pH of early endosomes. Interestingly, the dissociation of HL12 and HL32 from CTLA-4 seemed to allow the CTLA-4 molecule to escape lysosomal degradation.

Even in the absence of ligand binding, CTLA-4 is known to be constitutively internalized and recycled through a mechanism involving interactions with the LRBA protein. Given that HL12 and HL32 induce internalization of CTLA-4, but don’t induce lysosomal degradation or reduction of CTLA-4 on the cell surface, Zhang, Du, and Liu et al. suspected that ipilimumab and TremeIgG1 interfered with CTLA-4 recycling, while HL12 and HL32 did not. To test this hypothesis, the researchers tested the anti-CTLA-4 antibodies in cells with a mutant CTLA-4 that was incapable of binding LRBA and being recycled. In these cells, all four antibodies induced comparable CTLA-4 downregulation. Furthermore, in cells with wild-type CTLA-4, complexes of bound ipilimumab/CTLA-4 did not associate with LRBA. These results suggest that LRBA is essential to CTLA-4 recycling, and that bound antibodies prevent CTLA-4 from binding to LRBA, thereby preventing CTLA-4 recycling and instead driving the complex towards lysosomal degradation.

To determine whether CTLA-4 recycling was related to the reduced incidents of irAEs observed with HL12 and HL32, the researchers used Primaquine (PQ) to block endocytic recycling. In vitro, PQ increased CTLA-4 downregulation in response to HL12, but not ipilimumab. In mice treated with anti-PD-1 (to sensitize them to irAEs) and either control antibody, TremeIgG1, or H12, the inclusion of PQ increased the toxicity of HL12, but did not further increase the toxicity of the already toxic TremeIgG1. This indicated that disrupted CTLA-4 recycling results in robust CTLA-4 downregulation and that CTLA-4 downregulation is related to the induction of irAEs.

In an effort to reduce the risk of irAEs in CTLA-4-targeted therapies, Zhang, Du, and Liu et al. tested whether they could make TremeIgG1 more sensitive to pH by replacing tyrosine with histidine in the complementary determining regions of the antibody. Using this strategy, they were able to generate variants of TremeIgG1 that were more sensitive to pH than HL12. The more pH-sensitive variants reduced the amount of antibody-associated CTLA-4 in cells, increased the amount of membrane-associated CTLA-4, and did not appear to drive CTLA-4 towards lysosomal degradation. This indicated that increased pH sensitivity allowed antibodies to dissociate from CTLA-4 after endocytosis, leaving room for CTLA-4 to interact with LRBA and be recycled to the cell surface rather than degraded in the lysosomes. In young, humanized (CTLA-4h/h) mice treated with anti-PD-1 (to sensitize them to irAEs) the pH-sensitive TremeIgG1 variants were less toxic than wild-type TremeIgG1, showing less evidence of severe irAEs and increasing the two-month survival rate from 10% to 86%. Although not demonstrated directly, the authors speculate that the reduced downregulation of CTLA4 in peripheral Tregs is responsible for the reduced irAEs with pH sensitive antibodies.

With the pH-sensitive variant TremeIgG1 antibodies showing a dramatically stronger safety profile than wild-type TremeIgG1, the researchers wondered whether the efficacy or bioavailability of the pH-sensitive antibodies was also altered. Tracking the antibodies within the cell, the researchers found that while pH-insensitive antibodies were degraded in lysosomes along with CTLA-4, pH-sensitive antibodies, such as the variant TremeIgG1, dissociated from CTLA-4 under the acidic conditions in the endosome and instead entered into recycling vesicles and re-accumulated in the supernatant. This led to an increased bioavailability of antibodies, which was associated with increased ADCC.

Both pH-sensitive and pH-insensitive CTLA-4-targeting antibodies are effective at treating small tumors. In the setting of large, established MC38 colon carcinoma tumors, however, pH-sensitive antibodies (HL12 and HL32) were faster and more effective than pH-insensitive ipilimumab at depleting Tregs, and showed more potent antitumor efficacy. Similar results were observed when pH-sensitive TremeIgG1 variants were compared against pH-insensitive wild-type TremeIgG1, with the pH-sensitive variants showing enhanced bioavailability and ADCC in vitro, and increased Treg depletion and enhanced antitumor efficacy, including a higher rate of complete tumor rejection, in vivo.

Overall, Zhang, Du, and Liu et al. show that using pH-sensitive antibodies to target CTLA-4 allows for recycling of both the antibody and the target molecule, thereby enhancing both the efficacy and safety of the treatment. Altering existing antibodies in a way that sensitizes them to changes in pH might serve as a simple and effective way to improve the clinical application of CTLA-4-targeted antibodies.

by Lauren Hitchings

Meet the Researcher

This week, we asked our 3 questions to first co-author Yan Zhang and lead authors Pan Zheng and Yang Liu.

From left to right: Yan Zhang, Pan Zheng and Yang Liu

What prompted you to tackle this research question?
Immunotherapy-related adverse events (irAE) are becoming a bottleneck that prevents immunotherapy to reach its full potential to cure cancer. Among anti-CTLA-4 antibodies that cause tumor rejections, we have identified those that are toxic and those that are quite safe, but we were not sure what makes them different.

What was the most surprising finding of this study for you?

A eureka moment came to us when Yan followed the fate of anti-CTLA-4 antibodies inside the cell: the toxic antibodies moved quickly into big clusters and the antibodies that cause no toxicity also got inside the cells, but remained within much smaller vesicles within the cells! The differential trafficking of the antibodies inspired a series of experiments that clearly showed that the toxic antibodies drove CTLA-4 into lysosomal degradation, while the safe anti-CTLA-4 antibodies allowed recycling of CTLA-4 molecules. Further studies showed that it is the pH-dependent interaction between anti-CTLA-4 antibodies and their target that makes an antibody safe in humans. This conclusion was reached after extensive pharmacological and genetic studies in vivo and through extensive antibody studies in vitro.

What was the coolest thing you’ve learned (about) recently outside of the lab?

Science is cool


Zhang Y., Du X., Liu M., Tang F., Zhang P., Ai C., Fields J.K., Sundberg E.J., Latinovic O.S., Devenport M., Zheng P., Liu Y. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res. 2019 Jul 2.

In the Spotlight...

REVIEW: Alternative tumour-specific antigens

Smith et al. summarized the developing field of alternative tumor specific antigens (aTSAs) with the goal of increasing the repertoire of available therapeutic TSA targets for immunotherapy beyond the well-studied SNVs. Patient- and cancer-specific aTSAs arise from frameshift mutations, gene fusions, splicing and alternative translation variants, and endogenous retroelements and are highly specific and have the potential to be highly immunogenic. Powerful new computational tools have aided their prediction. Since several classes of aTSAs are shared across different tumors, off-the shelf therapies are possible.

Contributed by Katherine Turner

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

Tyrosine kinase inhibitor dasatinib blocked the activation, cytokine production, proliferation, and cytolytic activity of resting and, to a lesser extent, activated CAR T cells in vitro by blocking the phosphorylation of LCK, CD3ζ, and ZAP70, and limiting the induction of NFAT. Dasatinib inhibited CAR T cell function even in the presence of endogenous TCR stimulation. The induced “off” state persisted for up to 7 days, was rapidly and completely reversible upon dasatinib discontinuation, and did not reduce CAR T cell viability. In mice, dasatinib reversibly paused CAR T cell antitumor activity and prevented early-onset cytokine release syndrome.

Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection

Ebrahimi-Nik et al. utilized genomics, unbiased discovery mass spectrometry (MS) immunopeptidomics, and targeted MS validation analyses on mouse fibrosarcoma tumors to identify tumor neoepitopes. MS-identified, very weakly MHC-I-binding neoepitopes (previously unappreciated and typically assumed to be non-immunogenic) were presented by MHC-I molecules and mediated CD8+ T cell-dependent tumor rejection in vivo. Structural modeling elucidated how mutations can reconfigure the neoepitope conformation to increase its exposed hydrophobic surface area and enhance TCR binding.

CLINICAL TRIAL: Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

In a phase III clinical trial, 706 patients with unresectable stage III/IV melanoma received pembrolizumab (anti-PD-1) with either placebo or epacadostat (IDO1 inhibitor). No significant differences in median PFS (4.9 versus 4.7 months) or median OS (endpoint not reached) were observed between placebo/pembro and epacadostat/pembro groups. Objective response was 32% and 34%, respectively, with 4% of patients in each group achieving CR. About 10% of patients in each group had serious treatment-related adverse events. Despite encouraging early-phase clinical trial results, epacadostat did not enhance the efficacy of pembrolizumab in this trial.

Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy

To reduce the cost of CD8+ T cell isolation for CAR-T manufacturing and eliminate residual antibody from microbead techniques, Kacherovsky and Cardle et al. used an iterative selection process to identify DNA aptamers that selectively bind CD8α with high affinity. Complementary oligonucleotide binding to aptamer disrupted secondary structure by strand displacement and released bound CD8+ T cells. CD8+ T cells isolated from blood using aptamers or standard CD8 microbeads had comparable yield and purity and, when manufactured into CAR-T cells, displayed similar gene expression and antitumor efficacy in a mouse model of B cell lymphoma.

Contributed by Alex Najibi

Rebalancing protein homeostasis enhances tumor antigen presentation

Jaeger et al. showed that low-dose, sustained inhibition of the molecular chaperone heat shock protein 90 (HSP90) increased MHC-I surface expression and expanded the presented peptide repertoire on MC38 tumor cells in vitro, and slowed tumor growth in mice with an intact, but not deficient, immune system, independent of IFNγ signaling. Unlike the high-dose, bolus administration tested clinically, the dosage in this study was not immunosuppressive and did not induce a compensatory heat-shock response. HSP90 inhibitor in combination with agonist CD40/Poly(I:C) prolonged survival in MC38 tumor-bearing mice better than either monotherapy.

Everything New this Week In...

Close Modal